关注
Sheng-Yu Ku
Sheng-Yu Ku
Dana-Farber Cancer Institute
在 dfci.harvard.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
SY Ku, S Rosario, Y Wang, P Mu, M Seshadri, ZW Goodrich, ...
Science 355 (6320), 78-83, 2017
9162017
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer
P Mu, Z Zhang, M Benelli, WR Karthaus, E Hoover, CC Chen, ...
Science 355 (6320), 84-88, 2017
9102017
Towards precision oncology in advanced prostate cancer
SY Ku, ME Gleave, H Beltran
Nature Reviews Urology 16 (11), 645-654, 2019
2002019
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer
H Beltran, A Romanel, V Conteduca, N Casiraghi, M Sigouros, ...
The Journal of clinical investigation 130 (4), 1653-1668, 2020
1592020
YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage
E Ciamporcero, H Shen, S Ramakrishnan, S Yu Ku, S Chintala, L Shen, ...
Oncogene 35 (12), 1541-1553, 2016
1262016
Transcriptional mediators of treatment resistance in lethal prostate cancer
MX He, MS Cuoco, J Crowdis, A Bosma-Moody, Z Zhang, K Bi, A Kanodia, ...
Nature medicine 27 (3), 426-433, 2021
1162021
TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup
DP Labbé, CJ Sweeney, M Brown, P Galbo, S Rosario, KM Wadosky, ...
Clinical Cancer Research 23 (22), 7072-7083, 2017
1132017
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models
E Ciamporcero, KM Miles, R Adelaiye, S Ramakrishnan, L Shen, SY Ku, ...
Molecular cancer therapeutics 14 (1), 101-110, 2015
1102015
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
SC Baca, DY Takeda, JH Seo, J Hwang, SY Ku, R Arafeh, T Arnoff, ...
Nature Communications 12 (1), 1979, 2021
952021
Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer
L Ellis, SY Ku, S Ramakrishnan, E Lasorsa, G Azabdaftari, A Godoy, R Pili
Oncotarget 4 (12), 2225, 2013
862013
Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications
R Adelaiye, E Ciamporcero, KM Miles, P Sotomayor, J Bard, M Tsompana, ...
Molecular cancer therapeutics 14 (2), 513-522, 2015
722015
Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma
NP Damayanti, JA Budka, HWZ Khella, MW Ferris, SY Ku, E Kauffman, ...
Clinical Cancer Research 24 (23), 5977-5989, 2018
702018
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer
JS Kirk, K Schaarschuch, Z Dalimov, E Lasorsa, SY Ku, S Ramakrishnan, ...
Oncotarget 6 (5), 3136, 2015
662015
SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy
V Conteduca, SY Ku, L Puca, M Slade, L Fernandez, J Hess, R Bareja, ...
Molecular cancer therapeutics 19 (5), 1157-1164, 2020
602020
HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma
S Ramakrishnan, SY Ku, E Ciamporcero, KM Miles, K Attwood, S Chintala, ...
BMC cancer 16, 1-15, 2016
552016
Epigenetics in prostate cancer: clinical implications
V Conteduca, J Hess, Y Yamada, SY Ku, H Beltran
Translational andrology and urology 10 (7), 3104, 2021
402021
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer
MK Bakht, Y Yamada, SY Ku, VB Venkadakrishnan, JA Korsen, ...
Nature cancer 4 (5), 699-715, 2023
392023
Activated ALK cooperates with N-Myc via Wnt/β-catenin signaling to induce neuroendocrine prostate cancer
K Unno, ZR Chalmers, S Pamarthy, R Vatapalli, Y Rodriguez, B Lysy, ...
Cancer research 81 (8), 2157-2170, 2021
342021
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis
V Conteduca, SY Ku, L Fernandez, A Dago-Rodriquez, J Lee, A Jendrisak, ...
NPJ precision oncology 5 (1), 76, 2021
302021
Generation of a C57BL/6 MYC‐Driven Mouse Model and Cell Line of Prostate Cancer
L Ellis, SY Ku, Q Li, G Azabdaftari, J Seliski, B Olson, CS Netherby, ...
The Prostate 76 (13), 1192-1202, 2016
272016
系统目前无法执行此操作,请稍后再试。
文章 1–20